Non-small Cell Lung Cancer (NSCLC) has become the most prominent example demonstrating the importance of targeted therapy in cancer treatment. Up to 25% of patients with non-squamous NSCLC (nsNSCLC) harbor driver mutations which are responsible for the malignancy. For these patients, oral targeted drugs directed against the mutated gene yield better outcomes than chemotherapy or immunotherapy. Consequently, assessing the tumor for driver mutations has become standard of care in managing nsNSCLC. However, in 20% of lung cancer patients, the tissue biopsy is either unobtainable or insufficient to assay. In these circumstances, analyzing circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) from the blood can reveal the driver mutations. A prospective study was conducted with Biocept, to evaluate the clinical utility of a single gene assay using ctDNA and CTCs in patients with advanced NSCLC. Here, we report the comparison between biomarker expression of the tumor tissue and liquid biopsy of matched samples of 40 unique patients. Methods: Matched liquid biopsy and tumor tissue was analyzed from forty unique patients with stage III and IV NSCLC for EGFR, KRAS, BRAF, ALK, and ROS-1. Tissue was analyzed by Next Generation Sequencing (NGS), whereas peripheral blood samples for liquid biopsy was analyzed using circulating tumor DNA (ctDNA) for EGFR, KRAS, and BRAF mutations, and circulating tumor cells (CTCs) for ALK and ROS-1 mutations. Results: 80% of the patients (32/40) received both tissue biopsy and liquid biopsy analysis. The concordance between EGFR, KRAS, BRAF, ALK and ROS-1 between tumor tissue and liquid biopsy was 86%. Furthermore, liquid biopsy demonstrated a higher rate of conclusive results compared to tissue biopsy and led to a change in treatment for in 4 of the 40 patients. Conclusion: This works suggests that tissue and liquid biopsy can be complementary, and liquid biopsy can inform the course of treatment when a tissue biopsy is not available.
| Published in | International Journal of Biomedical Engineering and Clinical Science (Volume 8, Issue 3) |
| DOI | 10.11648/j.ijbecs.20220803.12 |
| Page(s) | 33-39 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Non-small Cell Lung Cancer, Liquid Biopsy, Cell-Free Tumor DNA, Circulating Tumor Cells, Driver Mutations
| [1] | Alix-Panabières C, Pantel K (2016) Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. Cancer Discov 6 (5): 479–491. https://doi.org/10.1158/2159-8290.CD-15-1483 |
| [2] | Mattox AK, Bettegowda C, Zhou S, Papadopoulos N, Kinzler KW, Vogelstein B (2019) Applications of liquid biopsies for cancer. Sci Transl Med 11 (507): eaay1984. https://doi.org/10.1126/scitranslmed.aay1984 |
| [3] | Karachaliou N, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R (2015) Real-time liquid biopsies become a reality in cancer treatment. Ann Transl Med 3 (3): 36. https://doi.org/10.3978/j.issn.2305-5839.2015.01.16 |
| [4] | Bai Y, Zhao H (2018) Liquid biopsy in tumors: opportunities and challenges. Ann Transl Med 6 (Suppl 1): S89. https://doi.org/10.21037/atm.2018.11.31 |
| [5] | Marrugo-Ramírez J, Mir M, Samitier J (2018) Blood-Based Cancer Biomarkers in Liquid Biopsy: A Promising Non-Invasive Alternative to Tissue Biopsy. Int J Mol Sci 19 (10): E2877. https://doi.org/10.3390/ijms19102877 |
| [6] | Kim TE, Murren JR (2002) Therapy for stage IIIB and stage IV non-small cell lung cancer. Clin Chest Med 23 (1): 209–224. https://doi.org/10.1016/s0272-5231(03)00069-8 |
| [7] | National Comprehensive Cancer Network. Non-small cell lung cancer (version 4.2021). https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf |
| [8] | Hanna NH, Robinson AG, Temin S, Baker S, Brahmer JR, Ellis PM, Gaspar LE, Haddad RY, Hesketh PJ, Jain D, Jaiyesimi I, Johnson DH, Leighl NB, Moffitt PR, Phillips T, Riely GJ, Rosell R, Schiller JH, Schneider BJ, Singh N, Spigel DR, Tashbar J, Masters G (2021) Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. J Clin Oncol 39 (9): 1040–1091. https://doi.org/10.1200/JCO.20.03570 |
| [9] | Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (21): 2129–2139. https://doi.org/10.1056/NEJMoa040938 |
| [10] | Poole JC, Wu S-F, Lu TT, Vibat CRT, Pham A, Samuelsz E, Patel M, Chen J, Daher T, Singh VM, Arnold LJ (2019) Analytical validation of the Target Selector ctDNA platform featuring single copy detection sensitivity for clinically actionable EGFR, BRAF, and KRAS mutations. PLoS One 14 (10): e0223112. https://doi.org/10.1371/journal.pone.0223112 |
| [11] | National Cancer Institute. SEER Cancer Stat Facts: Lung and Bronchus Cancer. (online) Available at: https://seer.cancer.gov/statfacts/html/lungb.html. |
| [12] | Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su W-C, Gray JE, Lee S-M, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS, FLAURA Investigators (2018) Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 378 (2): 113–125. https://doi.org/10.1056/NEJMoa1713137 |
| [13] | Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY-S, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC (2018) Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. New England Journal of Medicine 378 (22): 2078–2092. https://doi.org/10.1056/NEJMoa1801005 |
| [14] | Disis ML (2014) Mechanism of action of immunotherapy. Semin Oncol 41 Suppl 5: S3-13. https://doi.org/10.1053/j.seminoncol.2014.09.004 |
| [15] | Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M, Hui R, Hochmair MJ, Clingan P, Powell SF, Cheng SY-S, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Garon EB, Novello S, Rubio-Viqueira B, Boyer M, Kurata T, Gray JE, Yang J, Bas T, Pietanza MC, Garassino MC (2020) Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 38 (14): 1505–1517. https://doi.org/10.1200/JCO.19.03136 |
| [16] | Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, Vandormael K, Riccio A, Yang J, Pietanza MC, Brahmer JR (2019) Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J Clin Oncol 37 (7): 537–546. https://doi.org/10.1200/JCO.18.00149 |
| [17] | Kawaguchi T, Koh Y, Ando M, Ito N, Takeo S, Adachi H, Tagawa T, Kakegawa S, Yamashita M, Kataoka K, Ichinose Y, Takeuchi Y, Serizawa M, Tamiya A, Shimizu S, Yoshimoto N, Kubo A, Isa S-I, Saka H, Matsumura A (2016) Prospective Analysis of Oncogenic Driver Mutations and Environmental Factors: Japan Molecular Epidemiology for Lung Cancer Study. J Clin Oncol 34 (19): 2247–2257. https://doi.org/10.1200/JCO.2015.64.2322 |
| [18] | Shi Y, Au JS-K, Thongprasert S, Srinivasan S, Tsai C-M, Khoa MT, Heeroma K, Itoh Y, Cornelio G, Yang P-C (2014) A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol 9 (2): 154–162. https://doi.org/10.1097/JTO.0000000000000033 |
| [19] | Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T, North-East Japan Study Group (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362 (25): 2380–2388. https://doi.org/10.1056/NEJMoa0909530 |
| [20] | Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin M-C, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria J-C, FLAURA Investigators (2020) Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med 382 (1): 41–50. https://doi.org/10.1056/NEJMoa1913662 |
| [21] | Ramirez RA, Lu J, Thomas KEH (2018) Quality of life for non-small cell lung cancer patients in the age of immunotherapy. Transl Lung Cancer Res 7 (Suppl 2): S149–S152. https://doi.org/10.21037/tlcr.2018.03.10 |
| [22] | Chan BA, Hughes BGM (2015) Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 4 (1): 36–54. https://doi.org/10.3978/j.issn.2218-6751.2014.05.01 |
| [23] | Hofman P (2019) The challenges of evaluating predictive biomarkers using small biopsy tissue samples and liquid biopsies from non-small cell lung cancer patients. J Thorac Dis 11 (Suppl 1): S57–S64. https://doi.org/10.21037/jtd.2018.11.85 |
| [24] | Kelly RJ, Turner R, Chen Y-W, Rigas JR, Fernandes AW, Karve S (2019) Complications and Economic Burden Associated With Obtaining Tissue for Diagnosis and Molecular Analysis in Patients With Non-Small-Cell Lung Cancer in the United States. J Oncol Pract 15 (8): e717–e727. https://doi.org/10.1200/JOP.18.00762 |
| [25] | Tuzi A, Bolzacchini E, Suter MB, Giaquinto A, Passaro A, Gobba S, Vallini I, Pinotti G (2017) Biopsy and re-biopsy in lung cancer: the oncologist requests and the role of endobronchial ultrasounds transbronchial needle aspiration. J Thorac Dis 9 (Suppl 5): S405–S409. https://doi.org/10.21037/jtd.2017.04.09 |
| [26] | Lazzari C, Gregorc V, Karachaliou N, Rosell R, Santarpia M (2020) Mechanisms of resistance to osimertinib. J Thorac Dis 12 (5): 2851–2858. https://doi.org/10.21037/jtd.2019.08.30 |
| [27] | Rijavec E, Coco S, Genova C, Rossi G, Longo L, Grossi F (2019) Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges. Cancers (Basel) 12 (1): 17. https://doi.org/10.3390/cancers12010017 |
| [28] | Remon J, Swalduz A, Planchard D, Ortiz-Cuaran S, Mezquita L, Lacroix L, Jovelet C, Rouleau E, Leonce C, De Kievit F, Morris C, Jones G, Mercier K, Howarth K, Green E, Pérol M, Saintigny P, Besse B (2020) Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay. PLoS One 15 (6): e0234302. https://doi.org/10.1371/journal.pone.0234302 |
| [29] | Leighl NB, Page RD, Raymond VM, Daniel DB, Divers SG, Reckamp KL, Villalona-Calero MA, Dix D, Odegaard JI, Lanman RB, Papadimitrakopoulou VA (2019) Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. Clin Cancer Res 25 (15): 4691–4700. https://doi.org/10.1158/1078-0432.CCR-19-0624 |
APA Style
Andrew Friday, Khaled Alhamad, Gene Grant Finley, Robin Raquel Rodriguez, Herman Lo, et al. (2022). Driver Mutations in Non-Small Cell Lung Cancer: Utility of Liquid Biopsy. International Journal of Biomedical Engineering and Clinical Science, 8(3), 33-39. https://doi.org/10.11648/j.ijbecs.20220803.12
ACS Style
Andrew Friday; Khaled Alhamad; Gene Grant Finley; Robin Raquel Rodriguez; Herman Lo, et al. Driver Mutations in Non-Small Cell Lung Cancer: Utility of Liquid Biopsy. Int. J. Biomed. Eng. Clin. Sci. 2022, 8(3), 33-39. doi: 10.11648/j.ijbecs.20220803.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijbecs.20220803.12,
author = {Andrew Friday and Khaled Alhamad and Gene Grant Finley and Robin Raquel Rodriguez and Herman Lo and Aaron Weidman and Zachary Otaibi and Ashish Sethi and Suneera Bhatia},
title = {Driver Mutations in Non-Small Cell Lung Cancer: Utility of Liquid Biopsy},
journal = {International Journal of Biomedical Engineering and Clinical Science},
volume = {8},
number = {3},
pages = {33-39},
doi = {10.11648/j.ijbecs.20220803.12},
url = {https://doi.org/10.11648/j.ijbecs.20220803.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijbecs.20220803.12},
abstract = {Non-small Cell Lung Cancer (NSCLC) has become the most prominent example demonstrating the importance of targeted therapy in cancer treatment. Up to 25% of patients with non-squamous NSCLC (nsNSCLC) harbor driver mutations which are responsible for the malignancy. For these patients, oral targeted drugs directed against the mutated gene yield better outcomes than chemotherapy or immunotherapy. Consequently, assessing the tumor for driver mutations has become standard of care in managing nsNSCLC. However, in 20% of lung cancer patients, the tissue biopsy is either unobtainable or insufficient to assay. In these circumstances, analyzing circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) from the blood can reveal the driver mutations. A prospective study was conducted with Biocept, to evaluate the clinical utility of a single gene assay using ctDNA and CTCs in patients with advanced NSCLC. Here, we report the comparison between biomarker expression of the tumor tissue and liquid biopsy of matched samples of 40 unique patients. Methods: Matched liquid biopsy and tumor tissue was analyzed from forty unique patients with stage III and IV NSCLC for EGFR, KRAS, BRAF, ALK, and ROS-1. Tissue was analyzed by Next Generation Sequencing (NGS), whereas peripheral blood samples for liquid biopsy was analyzed using circulating tumor DNA (ctDNA) for EGFR, KRAS, and BRAF mutations, and circulating tumor cells (CTCs) for ALK and ROS-1 mutations. Results: 80% of the patients (32/40) received both tissue biopsy and liquid biopsy analysis. The concordance between EGFR, KRAS, BRAF, ALK and ROS-1 between tumor tissue and liquid biopsy was 86%. Furthermore, liquid biopsy demonstrated a higher rate of conclusive results compared to tissue biopsy and led to a change in treatment for in 4 of the 40 patients. Conclusion: This works suggests that tissue and liquid biopsy can be complementary, and liquid biopsy can inform the course of treatment when a tissue biopsy is not available.},
year = {2022}
}
TY - JOUR T1 - Driver Mutations in Non-Small Cell Lung Cancer: Utility of Liquid Biopsy AU - Andrew Friday AU - Khaled Alhamad AU - Gene Grant Finley AU - Robin Raquel Rodriguez AU - Herman Lo AU - Aaron Weidman AU - Zachary Otaibi AU - Ashish Sethi AU - Suneera Bhatia Y1 - 2022/09/05 PY - 2022 N1 - https://doi.org/10.11648/j.ijbecs.20220803.12 DO - 10.11648/j.ijbecs.20220803.12 T2 - International Journal of Biomedical Engineering and Clinical Science JF - International Journal of Biomedical Engineering and Clinical Science JO - International Journal of Biomedical Engineering and Clinical Science SP - 33 EP - 39 PB - Science Publishing Group SN - 2472-1301 UR - https://doi.org/10.11648/j.ijbecs.20220803.12 AB - Non-small Cell Lung Cancer (NSCLC) has become the most prominent example demonstrating the importance of targeted therapy in cancer treatment. Up to 25% of patients with non-squamous NSCLC (nsNSCLC) harbor driver mutations which are responsible for the malignancy. For these patients, oral targeted drugs directed against the mutated gene yield better outcomes than chemotherapy or immunotherapy. Consequently, assessing the tumor for driver mutations has become standard of care in managing nsNSCLC. However, in 20% of lung cancer patients, the tissue biopsy is either unobtainable or insufficient to assay. In these circumstances, analyzing circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) from the blood can reveal the driver mutations. A prospective study was conducted with Biocept, to evaluate the clinical utility of a single gene assay using ctDNA and CTCs in patients with advanced NSCLC. Here, we report the comparison between biomarker expression of the tumor tissue and liquid biopsy of matched samples of 40 unique patients. Methods: Matched liquid biopsy and tumor tissue was analyzed from forty unique patients with stage III and IV NSCLC for EGFR, KRAS, BRAF, ALK, and ROS-1. Tissue was analyzed by Next Generation Sequencing (NGS), whereas peripheral blood samples for liquid biopsy was analyzed using circulating tumor DNA (ctDNA) for EGFR, KRAS, and BRAF mutations, and circulating tumor cells (CTCs) for ALK and ROS-1 mutations. Results: 80% of the patients (32/40) received both tissue biopsy and liquid biopsy analysis. The concordance between EGFR, KRAS, BRAF, ALK and ROS-1 between tumor tissue and liquid biopsy was 86%. Furthermore, liquid biopsy demonstrated a higher rate of conclusive results compared to tissue biopsy and led to a change in treatment for in 4 of the 40 patients. Conclusion: This works suggests that tissue and liquid biopsy can be complementary, and liquid biopsy can inform the course of treatment when a tissue biopsy is not available. VL - 8 IS - 3 ER -
Information
Email: